Ibex Investors’s Denali Therapeutics DNLI Stock Holding History

Ibex Investors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,011	Closed	-$209K	–	101
2019 Q1	$209K	Buy	+9,011	New	+$189K	0.02%	50

Other funds holding DNLI

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Ibex Investors's DNLI Position: Q2 2019 in Review

Ibex Investors sold out of Denali Therapeutics (DNLI) in Q2 2019, closing a stake of 9,011 shares — an estimated $209K sold.

Ibex Investors first reported a position in DNLI in Q1 2019 and held it in 1 quarter. The position peaked at $209K in Q1 2019. 114 funds tracked by Wall St. Rank hold DNLI as of Q2 2019.

Ibex Investors reported no remaining Denali Therapeutics position as of Q2 2019 after selling out during the quarter.
Ibex Investors sold 9,011 Denali Therapeutics shares in Q2 2019, an estimated $209K.
Ibex Investors first reported a position in Denali Therapeutics in Q1 2019 and held it in 1 quarter.
Ibex Investors's Denali Therapeutics position peaked at $209K in Q1 2019.
114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2019.

Based on Ibex Investors's 13F filing for Q2 2019, filed 29 Jul 2019.